⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GILD News
Gilead Sciences Inc
ER+/ HER2 - ve Breast Cancer Market Insight, Epidemiology, and Market Forecast Report 2022-2036
globenewswire.com
AZN
LLY
PFE
GILD
VERU
AHF Slams Gilead for Role in Florida AIDS Drug Crisis
businesswire.com
GILD
Minnesota Community Unites at 2026 Susan G. Komen ® Race for the Cure
businesswire.com
BAC
NTRA
GH
NVS
LLY
UNH
GILD
7MM Systemic Lupus Erythematosus and Lupus Nephritis Drug Market Analysis & Forecast 2024-2034: Future SLE and LN Players Competition, High Unmet Need for Steroid-sparing Treatments
globenewswire.com
ABBV
GSK
AZN
GILD
REGN
Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
businesswire.com
TEM
GILD
Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026
globenewswire.com
ASMB
GILD
Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise
businesswire.com
GILD
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
globenewswire.com
KYMR
GILD
SAS Innovate 2026 to feature new health care and life sciences AI capabilities and real-world use cases
prnewswire.com
JNJ
AZN
GILD
REGN
SNY
IQV
OGN
PFE
ABBV
ELV
CI
EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion USA - English USA - English
prnewswire.com
GILD